DICER1 hotspot mutations in non-epithelial gonadal tumours

L Witkowski[1,2,3], J Mattina[2], S Schönberger[4], M J Murray[5,6], D G Huntsman[7], J S Reis-Filho[8], W G McCluggage[9], J C Nicholson[5], N Coleman[6], G Calaminus[10], D T Schneider[11], J Arseneau[12], C J R Stewart[13] and W D Foulkes*,[1,2,3,14]

[1]Department of Oncology and Human Genetics, Program in Cancer Genetics, McGill University, Montreal, Quebec, Canada; [2]Department of Medical Genetics, Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, Quebec, Canada; [3]Department of Human Genetics, McGill University, Montreal, Quebec, Canada; [4]Department of Paediatric Haematology and Oncology, University of Bonn, University Children's Hospital, Bonn, Germany; [5]Department of Paediatric Oncology and Haematology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; [6]Department of Pathology, University of Cambridge, Cambridge, UK; [7]Departments of Pathology, Vancouver General Hospital, Centre for Translational and applied Genomics, the British Columbia Cancer Agency and the Genetic Pathology Evaluation Centre, Vancouver, British Columbia, Canada; [8]Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; [9]Department of Pathology, Royal Group of Hospitals Trust, Belfast, UK; [10]Department of Paediatric Haematology and Oncology, University of Münster, Münster, Germany; [11]Clinic of Paediatrics, Municipal Hospital Dortmund, Dortmund, Germany; [12]Department of Pathology, McGill University, Montreal, Quebec, Canada; [13]Department of Histopathology, King Edward Memorial Hospital, Perth, Australia and [14]Department of Medical Genetics, Research Institute, McGill University Health Centre, Montreal, Quebec, Canada

Background: Non-epithelial gonadal tumours largely comprise sex cord-stromal tumours (SCSTs) and germ cell tumours (GCTs). Specific somatic mutations in *DICER1*, a microRNA maturation pathway gene, have been identified in these tumours. We conducted a study that aimed to confirm, refine and extend the previous observations.

Methods: We used Sanger sequencing to sequence the RNase IIIa and IIIb domains of *DICER1* in 154 gonadal tumours from 135 females and 19 males, as well as 43 extra-gonadal GCTs from 26 females and 17 males.

Results: We identified heterozygous non-synonymous mutations in the RNase IIIb domain of *DICER1* in 14/197 non-epithelial tumours (7.1%). Mutations were found in 9/28 SCSTs (32%), 5/118 gonadal GCTs (4.2%), 0/43 extra-gonadal GCTs and 0/8 miscellaneous tumours. The 14 mutations affected only five residues: E1705, D1709, E1788, D1810 and E1813. In all five patients where matched and constitutional DNA was available, the mutations were only somatic. There were no mutations found in the RNase IIIa domain.

Conclusion: More than half (8/15) of Sertoli–Leydig cell tumours (SLCTs) harbour *DICER1* mutations in the RNase IIIb domain, while mutations are rarely found in GCTs. Genetic alterations in SLCTs may aid in classification and provide new approaches to therapy.

Non-epithelial ovarian tumours consist of sex cord-stromal tumours (SCSTs), germ cell tumours (GCTs), as well as other miscellaneous neoplasms such as lymphomas and soft tissue tumours (Table 1 (Scully, 1987)). Sex cord-stromal tumours and GCTs, respectively, comprise 8% and 3% of all ovarian malignancies in Western countries (Talerman and Vang, 2011; Young, 2011; Low *et al*, 2012). Although SCSTs can arise in women of all ages (Young, 2011), GCTs often develop in adolescence or early

adulthood and almost 70% of ovarian tumours occurring before the age of 20 years are germ cell in type (Low *et al*, 2012). GCTs can arise in both male and female patients; in adults, 90% develop in the gonad and the other 10% arise extra-gonadally, while in children, the tumours arise in gonadal and extra-gonadal sites with similar frequency (Giambartolomei *et al*, 2009; Arora *et al*, 2012). These tumours are sub-classified depending on the degree and direction of differentiation: germinomas (dysgerminomas in the ovary and seminomas in the testis), embryonal carcinomas, yolk sac tumours (also known as an endodermal sinus tumour), polyembryomas, choriocarcinomas, teratomas (mature and immature) and mixed malignant GCTs, which are composed of more than one tumour type (Table 1 (Scully, 1987)). Sex cord-stromal tumours are further categorised into granulosa-stromal cell tumours, Sertoli-stromal cell tumours (including Sertoli–Leydig cell tumours (SLCTs)), mixed and unclassified SCST, and steroid cell tumours (Table 1 (Scully, 1987)). The prognosis of SCSTs and GCTs is generally favourable, with an overall survival of 89% and 80%, respectively (Schneider *et al*, 2003; Luis and Coleman, 2011).

In addition to these non-epithelial tumours, other very rare and highly malignant ovarian tumours exist that fall under the 'miscellaneous tumours' category, with some categorised as small round cell tumours of childhood (Scully, 1987). These include, but are not limited to, small-cell carcinoma of the ovary, hypercalcaemic type and rhabdomyosarcoma (Table 1). Owing to the rarity of these tumours, they are difficult to comprehensively study and little is known about their biology or genetics.

DICER protein, encoded by the *DICER1* gene, has many functions, including virus and transposon defence, chromatin regulation, centromere integrity and most notably, control of gene expression as part of the microRNA (miRNA) pathway (Murchison and Hannon, 2004). MiRNAs are small (20–22 nucleotide) non-coding RNAs that regulate the translation of downstream target genes at their 3′-untranslated region and, as such, have an important role in virtually all biological processes. A mutation in any component of the miRNA processing pathway can potentially modify the expression of miRNAs, causing dysregulation of their target mRNA expression. MiRNAs are generally downregulated in cancer (Lu *et al*, 2005) and have been shown to function as both oncogenes and as tumour suppressors in their own right. As a member of the RNase III endonuclease family, DICER measures and cleaves all precursor miRNAs into mature miRNAs, and hence is an essential part of this pathway.

In recent years, the role of DICER in cancer progression and prognosis has been extensively studied. In several cancers, including lung, breast, ovarian and endometrial carcinoma, low levels of DICER expression are associated with poorer survival rates. Conversely, in prostate and colorectal cancers, higher expression of DICER has been shown to be associated with a worse prognosis (Bahubeshi *et al*, 2011). *DICER1* is the only gene in the miRNA pathway in which germline mutations predispose to a Mendelian disorder, which is characterised by a range of mainly paediatric-onset cancers (Bahubeshi *et al*, 2011). Germline mutations were first discovered in patients with pleuropulmonary blastoma (PPB), a rare lung tumour, who all had a family history of PPB or the related familial tumour dysplasia syndrome (PPB-FTDS, Online Mendelian Inheritance in Man (OMIM) number, 601200 (Hill *et al*, 2009)). This syndrome commonly includes cystic nephroma, ovarian SCSTs (particularly SLCTs), and multi-nodular goitre (Bahubeshi *et al*, 2011). Since then, additional rare neoplasms have been included in the DICER1 syndrome, when they were shown to be associated with deleterious germline *DICER1* mutations, including cervical embryonal rhabdomyosarcoma (ERMS), ciliary-body medulloepithelioma, pituitary blastoma, cervical primitive neuroectodermal tumour, juvenile intestinal hamartomatous polyps and Wilms tumour (Foulkes *et al*, 2011; Slade *et al*, 2011; Choong *et al*, 2012).

Table 1. Classification of non-epithelial and miscellaneous gonadal tumours

Sex cord-stromal tumours
Granulosa-stromal cell tumours
Granulosa cell tumour
Adult type
Juvenile type
Thecoma-Fibroma group
Thecoma
Fibroma-fibrosarcoma
Sclerosing stromal tumour
Sertoli-stromal cell tumours
Sertoli cell tumour
Stromal-Leydig cell tumour
Sertoli–Leydig cell tumour (androblastoma)
Sex cord-stromal tumours of mixed or unclassified type
Sex cord-tumour with annular tubules
Gynandroblastoma
Sex cord-stromal tumour, unclassified
Steroid cell tumours
Leydig cell tumours
Hilus cell tumour
Leydig cell tumour, non-hilar type
Germ cell tumours
Primitive germ cell tumours
Dysgerminoma
Yolk sac tumour
Embryonal carcinoma
Polyembryoma
Choriocarcinoma
Teratoma
Mature
Immature
Monodermal and highly specialised types
Mixed germ cell tumours
Germ cell sex cord-stromal tumours
Gonadoblastoma
Mixed germ cell-sex cord-stromal tumour
Miscellaneous ovarian tumours
Small cell carcinoma, hypercalcaemic type
Wilms tumour
Soft tissue tumours not specific to the ovary
Embryonal rhabdomyosarcoma
Adapted from Scully, 1987.

Somatic mutations in *DICER1* exist in the tumours of many of the patients who harbour germline mutations in this gene: such mutations were found in 30 of 102 (29%) of non-epithelial ovarian tumours. These somatic mutations affected the metal-binding sites of the RNase IIIb domain, and have been named 'hotspots' (Heravi-Moussavi *et al*, 2012). Furthermore, four of the patients with hotspot mutations from whom constitutional DNA was tested harboured an additional deleterious germline mutation.

Given that in the previous paper, discovery-based whole-exome sequencing of 14 non-epithelial ovarian tumours revealed deleterious somatic mutations only in the RNase III domains of *DICER1* (Heravi-Moussavi *et al*, 2012), and that a previous study, in which the entire *DICER1* gene was sequenced in 191 sporadic Wilms tumours, reported that three of the five identified missense

mutations were in the RNase IIIb domain (Wu *et al*, 2013), we accordingly focussed on the RNase III domains only. We sequenced the RNase IIIa and IIIb domains of *DICER1* in 154 non-epithelial ovarian and testicular tumours and in 43 extra-gonadal GCTs. In doing so, we provide a comprehensive follow-up of the initial study (Heravi-Moussavi *et al*, 2012). In sequencing a wide variety of tumour types, we refine the previous results, extend the phenotypes associated with somatic *DICER1* mutations in non-epithelial gonadal tumours and provide new data on the prevalence of *DICER1* mutations in these and other related tumours, such as extra-gonadal GCTs, ERMS and small-cell carcinoma of the ovary, hypercalcaemic type.

MATERIALS AND METHODS

Samples. The study was approved by the relevant institutional review boards: KEMH Ethics Board, WA on 18/06/2012, reference 1986/EW in Perth, the Multicenter Research Ethics Committee (ref: 02/4/071) and Local Research Ethics Committee (ref: 01/128) in Cambridge, the ethics board of the Heinrich-Heine-University in Düsseldorf, and the Institutional Review Board of the Faculty of Medicine of McGill University no. A00-M117-11A in Montreal. Participants provided written informed consent where applicable. Samples were acquired and tested in accordance with approvals obtained at the aforementioned sites. Eighty-six DNA samples from formalin-fixed paraffin-embedded (FFPE) gonadal tumours and 69 DNA samples from fresh-frozen gonadal tumours, as well as 32 constitutional DNA samples from these patients were collected and analysed (Supplementary Table S1). Of the total 154 gonadal tumours, 135 occurred in patients that were phenotypically female (Table 2a) and 19 arose in those that were phenotypically male (Table 2b). In addition, as few genetic studies have been performed on extra-gonadal GCTs, 43 extra-gonadal GCTs were analysed from 17 male and 26 female patients (Supplementary Figure S2). Furthermore, eight miscellaneous ovarian tumours were studied: seven cases of small-cell carcinoma of the ovary, hypercalcemic type and one ERMS. All tumours were reviewed by pathologists at the institution from which the samples were acquired or by central reference pathologists (Supplementary Table S1 and Supplementary Materials). The gonadal tumour types analysed are summarised in Tables 2a and b.

DNA extraction and Sanger sequencing. DNA was extracted from FFPE tumour samples using 3–5 slides of 10 μm thick tumour tissue with the QIAamp DNA FFPE Tissue Kit (QIAGEN, Toronto, ON, Canada) according to protocol. DNA from fresh-frozen tumour tissues was extracted using the DNeasy Blood and Tissue Kit (QIAGEN, Hilden, Germany). Sanger sequencing was used to screen the RNase IIIa and IIIb domains of *DICER1* in the tumour samples. Primer pairs for PCR amplification and sequencing were designed using Primer3 (http://frodo.wi.mit.edu/) to flank exons (Supplementary Materials). The sequences were then filtered using OligoCalc software (Kibbe, 2007) to avoid hairpin formation and UCSC *in silico* PCR software to ensure yield of a single product. DNA from any FFPE sample in which a mutation was found was extracted twice independently and the PCR was repeated at least twice from each independent extraction using QIAGEN HotStarTaq, 10 mM dNTP and 10 × PCR buffer reagents with 1.4 μl of 20 μM primers in a 50-μl reaction. Thermocycler parameters can be found in the Supplementary Materials. PCR products were purified and sequenced by conventional Sanger methods by the McGill University and Genome Quebec Innovation Centre. Sequences were analysed visually using Lasergene Version 10 (DNASTAR, Madison, WI, USA).

Table 2a. Ovarian tumours: histologial subtypes and frequency of DICER1 mutations

Tumours studied	Samples with mutation/total cases studied (%)
Sex cord-stromal tumours[a]	9/28 (32)
Sertoli–Leydig cell tumour	8/15 (53)
Juvenile granulosa cell tumour	0/4
Unclassified sex cord-stromal tumour	1/7 (14)
Leydig cell tumour	0/1
Sex cord-stromal tumour with annular tubules	0/1
Germ cell tumours[b]	3/99 (3)
Teratoma—mature	0/5
Teratoma—immature	0/15
Yolk sac tumour	0/20
Embryonal carcinoma	0/1
Mixed malignant germ cell tumour	2/14 (17)
Dyserminoma/gonadoblastoma	1/5 (20)
Dysgerminoma	0/39
Miscellaneous[c]	0/8
Embryonal rhabdomyosarcoma	0/1
Small-cell carcinoma of the ovary, hypercalcaemic type	0/7
Total	12/135 (9)

[a] Ages 7 months to 66 years (median age 16 years).
[b] Ages birth to 39 years (median age 17 years).
[c] Ages 15 to 46 years (median age 18 years).

Table 2b. Testicular tumours: histologial subtypes and frequency of DICER1 mutations

Tumours studied	Samples with mutation/total cases studied (%)
Germ cell tumours[a]	2/19 (10)
Teratoma—mature	0/2
Teratoma—immature	0/1
Yolk sac tumour	1/7 (14)
Embryonal carcinoma	0/1
Mixed malignant germ cell tumour	1/5 (20)
Seminoma	0/3
Total	2/19 (10)

[a] Ages 10 months to 25 years (median age 17 years).

RESULTS

Using Sanger sequencing, we analysed the RNase III domains of *DICER1* in 154 gonadal tumour samples of various types (Tables 2a and b) and in 43 extra-gonadal tumours (Supplementary Figure S2). We found 14 heterozygous mutations in *DICER1* affecting five different residues of RNase IIIb: E1705, D1709, E1788, D1810 and E1813 (Figure 1, Table 3). Although most of the codon changes were predicted to cause a non-synonymous amino-acid change, one variant (c.5438A > G) was recently shown to cause skipping of the entire exon 25, leading to a frameshift (p.E1788fsX41) (Wu *et al*, 2013). Matched constitutional DNA was not available for most tumours with mutations but in all five patients whose constitutional DNA was tested, the mutations were somatic.

Figure 1. Diagram of DICER protein and representative SLCT with mutation. (**A**) Example of poorly differentiated SLCT harbouring a hotspot mutation in *DICER1*, 20 × . (**B**) Top: hotspot mutation c.5437G>A found in (**A**), * denotes mutation. Bottom: wild-type. (**C**) Schematic of DICER protein (NP_001258211.1), listing all predicted amino-acid changes found in analysed samples. Numbers indicate amino-acid position.

Table 3. Summary of all mutations found				
Codon change	**Tumour types**	**Age of patient in years (gender)**	**Protein change**	**Previously reported (tumour types)**
c.5113G→A	Unclassified SCST	54 (F)	p.E1705K	Yes (ERMS, SLCT) (Heravi-Moussavi *et al*, 2012)
c.5125G→A	SLCT	21 (F)	p.D1709N	Yes (SLCT,TGCT,YST) (Heravi-Moussavi *et al*, 2012)
c.5428 G→T	Mixed GCT (YST/IT)	27 (F)	p.D1810Y	Yes (SLCT, ERMS, MT) (Heravi-Moussavi *et al*, 2012, Wu *et al*, 2013)
c.5429A→G[a]	Mixed gonadoblastoma/dysgerminoma	15 (F)	p.E1788fs*41	No
c.5429A→T	SLCT with components of JGCT	16 (F)	p.D1810V	No
c.5437G→A	SLCT	32 (F)	p.E1813K	Yes (SLCT) (Heravi-Moussavi *et al*, 2012)
c.5437G→C	SLCT SLCT	13 (F) 20 (F)	p.E1813Q	Yes (SLCT) (Heravi-Moussavi *et al*, 2012)
c.5438A→G[b]	Mixed GCT (dysgerminoma/YST) Mixed GCT (embryonal carcinoma/IT/choriocarcinoma) YST SLCT	9 (F) 12 (M) 1 (M) 24 (F)	p.E1788fs*41	Yes (SLCT, WT) (Heravi-Moussavi *et al*, 2012; Wu *et al*, 2013)
c.5439G→C	SLCT SLCT	16 (F) 30 (F)	p.E1813D	No

Abbreviations: ERMS = embryonal rhabdomyosarcoma; F = female; IT = immature teratoma; JGCT = juvenile granulosa cell tumour; M = male; MT = mature teratoma; SCST = sex cord-stromal tumour; SLCT = Sertoli–Leydig cell tumour; WT = Wilms tumour; YST = yolk sac tumour.
[a]Codon change is at D1810 but causes an A to G substitution causes a skip of exon 25 (unpublished data, Foulkes lab).
[b]Codon change is at E1813 but causes an A to G substitution causes a skip of exon 25.

The majority of mutations (8/14) were detected in ovarian SLCTs. One other mutation was observed in an unclassified SCST. Five mutations were found in gonadal GCTs (three females and two males). One of these mutations was in a yolk sac tumour (male), one in a mixed dysgerminoma/gonadoblastoma (mostly dysgerminoma, female) and three in mixed malignant GCTs, two

of which had a yolk sac tumour component (both females). Three of the five mutated GCTs harboured the same variation (c.5438A > G). No mutations were detected in any of the 43 extra-gonadal GCTs, in seven cases of small-cell carcinoma of the ovary, hypercalcaemic type or in the single case of ovarian ERMS. There was no significant difference between the ages of the patients with *DICER1* mutations (median age 18, range 20 months–54 years) and those without (median age 17 years, range birth–66 years), (*P* = 0.72, Student's two-tailed *t*-test). The results are summarised in Tables 2a and b and Supplementary Table S1.

DISCUSSION

DICER1 mutations in non-epithelial gonadal tumours. We found mutations in the RNase IIIb region of *DICER1* in 8 of 15 (53%) of ovarian SLCTs and in 14 of 154 (9%) of all gonadal tumours studied. Our results in SLCTs are consistent with the previous study (Heravi-Moussavi *et al*, 2012), in which *DICER1* hotspot mutations were identified in 26/43 SLCTs (60%). We also analysed seven unclassified SCSTs, and found one mutation. This demonstrates that in tumours where histological classification is difficult, such as in some undifferentiated SCSTs, mutation analysis may aid tumour classification. In addition, we tested seven cases of small-cell carcinoma of the ovary, hypercalcaemic type and one case of ovarian ERMS, but did not find any *DICER1* hotspot mutations. Our study also included extra-gonadal GCTs and a large series of ovarian GCTs of different histological types, and therefore we were able to expand upon earlier findings in these tumours.

Heravi-Moussavi *et al* (2012) identified mutations in 2/15 ovarian yolk sac tumours, whereas we did not find mutations in any of the 20 cases that we studied. However, our two *DICER1*-mutated mixed malignant ovarian GCTs did contain yolk sac components. Consistent with the findings of Heravi-Moussavi *et al* (2012), we analysed 44 dysgerminomas (five of which were associated with gonadoblastoma) and found only a single mutation, allowing us to conclude that mutations in *DICER1* hotspot mutations are rare in dysgerminomas but do occasionally occur.

Another recent study reported that somatic *DICER1* mutations in testicular GCTs are rare (De Boer *et al*, 2012). Although Heravi-Moussavi *et al* (2012) found a hotspot mutation in 1/14 testicular GCTs analysed, De Boer *et al* (2012) identified a mutation in just 1/96 tumours. In comparison, mutations were present in 2/19 testicular GCTs (one YST, one mixed malignant GCT) in the present series. Therefore, overall, somatic hotspot mutations in *DICER1* have been identified in 4/129 (3%) testicular GCTs investigated to date.

Sex cord-stromal tumours, GCTs and the DICER1 syndrome. As the discovery of the *DICER1* syndrome in patients with PPB, several studies have demonstrated the association between germline *DICER1* mutations and various types of ovarian SCSTs and GCTs (Rio Frio *et al*, 2011; Schultz *et al*, 2011; Slade *et al*, 2011). SLCTs are by far the most common non-epithelial ovarian tumour associated with the *DICER1* syndrome, and it is not clear whether germline *DICER1* mutations predispose to GCTs. Before identification of the responsible gene, a study described two families in which relatives of patients with PPB were diagnosed with testicular GCTs (Priest *et al*, 1996). Furthermore, 1 dysgerminoma and 3 seminomas have been reported in relatives of patients with *DICER1* germline mutations (Schultz *et al*, 2011), but no *DICER1* germline mutation was found in the only seminoma patient for which genetic information was available. Moreover, full sequencing of *DICER1* has revealed only a single SNV resulting in p.Q1580H in 228 probands with a GCT, at least 171 of whom had a positive family history of GCT (Slade *et al*, 2011; Sabbaghian *et al*, 2013).

All but one of the mutations we found were in either a tumour definitely associated with the *DICER1* syndrome (SCSTs), or in a GCT with a dysgerminoma or yolk sac component. It remains unclear whether somatic *DICER1* mutations can be causally related to dysgerminomas or pure yolk sac tumours, but if they are, the mutations occur substantially less frequently than in SCSTs, and germline mutations in *DICER1* are rarely associated with susceptibility to GCTs.

Mechanism of tumorigenesis. As previously reported, the mutations we found were clustered around the Mg^{2+} metal-binding sites of the RNase IIIb domain (Heravi-Moussavi *et al*, 2012). However, although these authors detected more mutations at D1709, we found that the majority occurred at D1810 and E1813. It was originally believed that *DICER1* mutations induced neoplasia via a haploinsufficient mechanism (Kumar *et al*, 2009), but more recent studies have shown that some patients with deleterious mutations on one allele of the gene also have a somatic, non-truncating, mutation on the other allele (Heravi-Moussavi *et al*, 2012; Wu *et al*, 2013). The specific locations of the mutations are more reminiscent of dominantly-acting oncogenes and it is likely that the hotspot-mutated alleles produce a viable, albeit dysfunctional, protein (Heravi-Moussavi *et al*, 2012). As the RNase IIIb domain requires the binding of two Mg^{2+} ions to catalyse the cleavage of the miRNA, improper binding due to an amino-acid change at any of these sites would presumably prevent DICER from processing its target miRNA. Recently, a model has been proposed whereby 5p strand miRNAs are not produced if the DICER protein is mutated at the RNase IIIb domain (Anglesio *et al*, 2013). As 5p strand miRNAs are more abundant than 3p strand miRNAs in targeting human mRNAs, loss of the former is likely to lead to increased levels of key proto-oncogenic mRNAs, potentiating tumour development (Anglesio *et al*, 2013).

This model may explain how such mutations result in tumorigenesis, but questions still remain as to (1) why germline *DICER1* mutations predispose to highly specific types of very rare cancers and (2) how identical somatic mutations can cause various different types of benign and malignant tumours. It has been suggested that as many of the tumours related to the *DICER1* syndrome possess an embryonal or primitive appearance, perhaps the effect of germline mutations is restricted to certain cell types during development (Heravi-Moussavi *et al*, 2012). The tumours associated with *DICER1* syndrome often occur in younger children, suggesting a developmental relationship. However, the contribution of *DICER1* mutations to the different tumours of the syndrome is variable. Although germline *DICER1* mutations may contribute significantly to cystic nephroma and SLCTs (Bahubeshi *et al*, 2010; Slade *et al*, 2011), they do not have as great an impact on the occurrence of Wilms tumour (Bahubeshi *et al*, 2010; Slade *et al*, 2011; Wu *et al*, 2013). DICER-null embryonic stem cells usually do not survive, but several cell-type specific conditional *DICER1* knockout models exist and experiments suggest that only a subset of differentiated cells are tolerant to a complete loss of *DICER1* (Gonzalez and Behringer, 2009; Iida *et al*, 2011; Nagalakshmi *et al*, 2011). It is plausible that the tissues in which tumours develop more frequently rely more on the function of DICER and miRNAs during development. Indeed, DICER has been shown to be necessary for postnatal differentiation and development of Müllerian duct mesenchyme-derived tissues of the female reproductive tract (Gonzalez and Behringer, 2009), as well as for nephrogenic development (Nagalakshmi *et al*, 2011).

Genetic studies such as those described in the current paper are important in potentially modifying or furthering tumour classification, as some tumours with similar histological appearances may have distinct genetic alterations. In the present study, one mutation-positive tumour had been diagnosed as an unclassified SCST, but it is possible that this tumour was in fact a poorly

differentiated SLCT. There is a constant evolution in the classification of neoplasia, and the identification of specific molecular abnormalities has the potential to enhance diagnostic accuracy and, ultimately, provide a rational approach to the development of novel treatment strategies (Bisogno *et al*, 2012). With advances in targeted therapies, it is likely that the identification of molecular alterations in gonadal SCSTs and GCTs will have increasing impact on diagnosis, treatment and outcome.

The two main limitations of our study were the small sample size for some of the histological subtypes, and the inability to test germline DNA in all of the patients with mutation-positive tumours to determine whether the identified mutations were germline or somatic events.

CONCLUSION

Through Sanger sequencing of 154 non-epithelial ovarian and testicular tumours, *DICER1* mutations were detected in 8/15 SLCTs, but only a small number of mutations in other types of tumours. Our data, when combined with the only previous publication on this subject (Heravi-Moussavi *et al*, 2012), demonstrate that 34/58 SLCTs (59%) possess RNase IIIb *DICER1* mutations. Due to the heterogeneous nature of SCSTs, the genetic differences between the tumours may aid in classification and provide new therapeutic approaches. A mutation was identified in one unclassified SCST, demonstrating that genetic testing may aid in the diagnosis of histologically problematic or previously unclassifiable tumour types.

The exact function of the observed *DICER1* mutations in the formation and progression of neoplasms presenting in patients with the *DICER1* syndrome remains unknown. If aberrant miRNAs have a more general causal role in these tumours, it is possible that the tumours without *DICER1* mutations have alterations in other factors in the miRNA processing pathway. Further investigations are likely to shed light on the exact role of these *DICER1* mutations in the formation of these rare tumours and other types of neoplasia, whether it be via miRNA maturation or through other *DICER1*-related functions.

ACKNOWLEDGEMENTS

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

Anglesio MS, Wang Y, Yang W, Senz J, Wan A, Heravi-Moussavi A, Salamanca C, Maines-Bandiera S, Huntsman DG, Morin GB (2013) Cancer-associated somatic DICER1 hotspot mutations cause defective miRNA processing and reverse-strand expression bias to predominantly mature 3p strands through loss of 5p strand cleavage. *J Pathol* **229**: 400–409.

Arora RS, Alston RD, Eden TOB, Geraci M, Birch JM (2012) Comparative incidence patterns and trends of gonadal and extragonadal germ cell tumors in England, 1979 to 2003. *Cancer* **118**: 4290–4297.

Bahubeshi A, Bal N, Rio Frio T, Hamel N, Pouchet C, Yilmaz A, Bouron-Dal Soglio D, Williams GM, Tischkowitz M, Priest JR, Foulkes WD (2010) Germline DICER1 mutations and familial cystic nephroma. *J Med Genet* **47**: 863–866.

Bahubeshi A, Tischkowitz M, Foulkes WD (2011) miRNA processing and human cancer: DICER1 cuts the mustard. *Sci Transl Med* **3**: 111ps46.

Bisogno G, Cecchetto G, Ferrari A (2012) Very rare tumours in paediatric age—from 'Tumori Rari in Età Pediatrica' to the European Cooperative Study Group for paediatric rare tumours. *Eur Oncol Haematol* **8**: 130–134.

Choong CS, Priest JR, Foulkes WD (2012) Exploring the endocrine manifestations of DICER1 mutations. *Trends Mol Med* **18**: 503–505.

De Boer C, Eini R, Gillis A, Stoop H, Looijenga L, White S (2012) DICER1 RNase IIIb domain mutations are infrequent in testicular germ cell tumours. *BMC Res Notes* **5**: 569.

Foulkes WD, Bahubeshi A, Hamel N, Pasini B, Asioli S, Baynam G, Choong CS, Charles A, Frieder RP, Dishop MK, Graf N, Ekim M, Bouron-Dal Soglio D, Arseneau J, Young RH, Sabbaghian N, Srivastava A, Tischkowitz MD, Priest JR (2011) Extending the phenotypes associated with DICER1 mutations. *Hum Mutat* **32**: 1381–1384.

Giambartolomei C, Mueller CM, Greene MH, Korde LA (2009) A mini-review of familial ovarian germ cell tumors: An additional manifestation of the familial testicular germ cell tumor syndrome. *Cancer Epidemiol* **33**: 31–36.

Gonzalez G, Behringer RR (2009) Dicer is required for female reproductive tract development and fertility in the mouse. *Mol Reprod Dev* **76**: 678–688.

Heravi-Moussavi A, Anglesio M, Cheng S, Senz J, Yang W, Prentice L, Fejes A, Chow C, Tone A, Kalloger S, Hamel N, Roth A, Ha G, Wan A, Maines-Bandiera S, Salamanca C, Pasini B, Clarke B, Lee A, Lee C, Zhao C, Young R, Aparicio S, Sorensen P, Woo M, Boyd N, Jones S, Hirst M, Marra M, Gilks B, Shah SP, Foulkes WD, Morin GB, Huntsman DG (2012) Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. *N Engl J Med* **366**: 234–242.

Hill DA, Ivanovich J, Priest JR, Gurnett CA, Dehner LP, Desruisseau D, Jarzembowski JA, Wikenheiser-Brokamp KA, Suarez BK, Whelan AJ, Williams G, Bracamontes D, Messinger Y, Goodfellow PJ (2009) DICER1 mutations in familial pleuropulmonary blastoma. *Science* **325**: 965.

Iida A, Shinoe T, Baba Y, Mano H, Watanabe S (2011) Dicer plays essential roles for retinal development by regulation of survival and differentiation. *Invest Ophthalmol Vis Sci* **52**: 3008–3017.

Kibbe WA (2007) OligoCalc: an online oligonucleotide properties calculator. *Nucleic Acids Res* **35** (webserver issue); e-pub ahead of print 25 May 2007.

Kumar MS, Pester RE, Chen CY, Lane K, Chin C, Lu J, Kirsch DG, Golub TR, Jacks T (2009) Dicer1 functions as a haploinsufficient tumor suppressor. *Genes Dev* **23**: 2700–2704.

Low JJH, Ilancheran A, Ng JS (2012) Malignant ovarian germ-cell tumours. *Best Pract Res Clin Obstet Gynaecol* **26**: 347–355.

Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR (2005) MicroRNA expression profiles classify human cancers. *Nature* **435**: 834–838.

Luis IV, Coleman R (2011) Ovarian germ cell malignancy: a heterogeneous tumour requiring supra-regional management. *Eur J Gynaecol Oncol* **32**: 387–392.

Murchison EP, Hannon GJ (2004) miRNAs on the move: miRNA biogenesis and the RNAi machinery. *Curr Opin Cell Biol* **16**: 7.

Nagalakshmi VK, Ren Q, Pugh MM, Valerius MT, Mcmahon AP, Yu J (2011) Dicer regulates the development of nephrogenic and ureteric compartments in the mammalian kidney. *Kidney Int* **79**: 317–330.

Priest JR, Watterson J, Strong L, Huff V, Woods WG, Byrd RL, Friend SH, Newsham I, Amylon MD, Pappo A, Mahoney DH, Langston C, Heyn R, Kohut G, Freyer DR, Bostrom B, Richardson MS, Barredo J, Dehner LP

(1996) Pleuropulmonary blastoma: a marker for familial disease. *J Pediatr* **128**: 220–224.

Rio Frio T, Bahubeshi A, Kanellopoulou C, Hamel N, Niedziela M, Sabbaghian N, Pouchet C, Gilbert L, O'brien PK, Serfas K, Broderick P, Houlston RS, Lesueur F, Bonora E, Muljo S, Schimke RN, Bouron-Dal Soglio D, Arseneau J, Schultz KA, Priest JR, Nguyen V-H, Harach HR, Livingston DM, Foulkes WD, Tischkowitz M (2011) DICER1 mutations in familial multinodular goiter with and without ovarian Sertoli-Leydig cell tumors. *JAMA* **305**: 68–77.

Sabbaghian N, Bahubeshi A, Shuen A, Kanetsky P, Tischkowitz M, Nathanson K, Foulkes W (2013) Germ-line DICER1 mutations do not make a major contribution to the etiology of familial testicular germ cell tumours. *BMC Res Notes* **6**: 127.

Schneider DT, Calaminus G, Wessalowksi R, Pathmanathan R, Selle B, Sternschulte W, Harms D, Göbel U (2003) Ovarian sex cord–stromal tumors in children and adolescents. *J Clin Oncol* **21**: 2357–2363.

Schultz KaP, Pacheco MC, Yang J, Williams GM, Messinger Y, Hill DA, Dehner LP, Priest JR (2011) Ovarian sex cord-stromal tumors, pleuropulmonary blastoma and DICER1 mutations: a report from the International Pleuropulmonary Blastoma Registry. *Gynecol Oncol* **122**: 246–250.

Scully RE (1987) Classification of human ovarian tumors. *Environ Health Perspect* **73**: 15–25.

Slade I, Bacchelli C, Davies H, Murray A, Abbaszadeh F, Hanks S, Barfoot R, Burke A, Chisholm J, Hewitt M, Jenkinson H, King D, Morland B, Pizer B, Prescott K, Saggar A, Side L, Traunecker H, Vaidya S, Ward P, Futreal PA, Vujanic G, Nicholson AG, Sebire N, Turnbull C, Priest JR, Pritchard-Jones K, Houlston R, Stiller C, Stratton MR, Douglas J, Rahman N (2011) DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome. *J Med Genet* **48**: 273–278.

Talerman A, Vang R (2011) Germ Cell Tumors of the Ovary. In *Blaustein's Pathology of the Female Genital Tract*. 6th edn. Kurman R. J., Ellenson L. H., Ronnett B. M. (eds) Springer: New York, NY, USA, pp 847–907.

Wu MK, Sabbaghian N, Xu B, Addidou-Kalucki S, Bernard C, Zou D, Reeve AE, Eccles M, Cole C, Choong CS, Charles A, Tan TY, Iglesias DM, Goodyer PR, Foulkes WD (2013) Biallelic DICER1 mutations occur in Wilms tumours. *J Pathol* **230**: 154–164.

Young RH (2011) Sex Cord-stromal, steroid cell, and other ovarian tumors with endocrine, paraendocrine, and paraneoplastic manifestations. In *Blaustein's Pathology of the Female Genital Tract*. 6th edn. Kurman R. J., Ellenson L. H., Ronnett B. M. (eds) Springer: New York, NY, USA, pp 785–846.

Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)